Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis

Background: Cognitive dysfunction occurs at the earliest stages of multiple sclerosis (MS), including the stage of clinically isolated syndrome (CIS). Methods: We evaluated the impact of interferon beta-1b (IFNβ-1b) 250 µg on cognitive performance during the CIS stage in the BENEFITstudy. Cognition...

Descripción completa

Detalles Bibliográficos
Autores principales: Penner, Iris-Katharina, Stemper, Brigitte, Calabrese, Pasquale, Freedman, Mark S, Polman, Chris H, Edan, Gilles, Hartung, Hans-Peter, Miller, David H, Montalbán, Xavier, Barkhof, Frederik, Pleimes, Dirk, Lanius, Vivian, Pohl, Christoph, Kappos, Ludwig, Sandbrink, Rupert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2012
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573673/
https://www.ncbi.nlm.nih.gov/pubmed/22492127
http://dx.doi.org/10.1177/1352458512442438
Descripción
Sumario:Background: Cognitive dysfunction occurs at the earliest stages of multiple sclerosis (MS), including the stage of clinically isolated syndrome (CIS). Methods: We evaluated the impact of interferon beta-1b (IFNβ-1b) 250 µg on cognitive performance during the CIS stage in the BENEFITstudy. Cognition was assessed by Paced Auditory Serial Addition Test-3” (PASAT-3”) scores. Results: Improvement in PASAT-3” score from baseline to year two was greater for IFNβ-1b treatment than placebo in patients not reaching clinically definite MS (CDMS) by year two. The treatment effect was maintained at year five and was statistically significant. Conclusions: To conclude, early IFNβ-1b treatment had a sustained positive effect on PASAT-3” score over the 5-year BENEFIT study.

Ejemplares similares